Skip to navigation Skip to content
  • The Cancer Letter on Facebook
  • The Cancer Letter on Twitter
  • The Cancer Letter on LinkedIn

The Cancer Letter

The leading source for information on the issues that shape oncology since 1973

Home
  • About
    • Our Readers
    • Our History
    • Our Contributors
    • Contact Us
    • Store
  • Current Issue
    • Past Issues
  • Podcast
    • The Directors
  • Events
  • Job Board
  • SUBSCRIBE
  • Login
  • SUBSCRIBE
  • Login
The Cancer Letter
Home
  • About
    • Our Readers
    • Our History
    • Our Contributors
    • Contact Us
    • Store
  • Current Issue
    • Past Issues
  • Podcast
    • The Directors
  • Events
  • Job Board
FDA grants breakthrough device designation for Natera’s MCED assay
Drugs & Targets

FDA grants breakthrough device designation for Natera’s MCED assay

October 23, 2026
Vol.52 No.39
FDA launches Rare Disease Framework Initiative for drug development
Cancer Policy

FDA launches Rare Disease Framework Initiative for drug development

October 16, 2026
Vol.52 No.38
FDA seeks nominations for the Tobacco Products Scientific Advisory Committee, announces new members
Cancer Policy

FDA seeks nominations for the Tobacco Products Scientific Advisory Committee, announces new members

October 16, 2026
Vol.52 No.38
FDA approves atezolizumab + chemotherapy for stage 3 colon cancer
Drugs & Targets

FDA approves atezolizumab + chemotherapy for stage 3 colon cancer

October 16, 2026
Vol.52 No.38
Drugs & Targets

FDA expands Anktiva approval for BCG-unresponsive non-muscle-invasive bladder cancer to cover both papillary and CIS disease

October 16, 2026
Vol.52 No.38
As FDA sidesteps the question of Galleri’s clinical benefit, NCI’s Letai has “some concerns”
Podcast

As FDA sidesteps the question of Galleri’s clinical benefit, NCI’s Letai has “some concerns”

October 14, 2026
Drugs & Targets

FDA approves tucatinib + trastuzumab + pertuzumab for maintenance treatment of HER2+ breast cancer

October 09, 2026
Vol.52 No.37
Two years after FDA’s breast density notification rule, there is still no standard for follow-up
Regulatory News

Two years after FDA’s breast density notification rule, there is still no standard for follow-up
So far, 38 million patients have received a dense breast notification. Now what?

October 02, 2026
Vol.52 No.36
By Claire Marie Porter
MD Anderson study suggests psilocybin may prevent chemo-induced neuropathy
Regulatory News

MD Anderson study suggests psilocybin may prevent chemo-induced neuropathy
“Because it works in one neural system, you begin to wonder: Well, what about another?”

October 02, 2026
Vol.52 No.36
By Sara Willa Ernst
FDA approves Degevma, a biosimilar for cancer-related bone complications
Drugs & Targets

FDA approves Degevma, a biosimilar for cancer-related bone complications

October 02, 2026
Vol.52 No.36

Posts navigation

Previous1234…69Next

Trending Stories

  • Brawley: ACS prostate cancer screening guideline should say no to “mass screening”
  • NCI’s Letai, FDA’s Diamantas identify strategies to speed up cancer trials
    Letai: 150 days to start a cancer trial is too long—cancer centers need to accept a little risk
  • ACS strengthens recommendation for prostate cancer screening
    Many will hear the endorsement and ignore the limitations
  • Kay “Taddy” Dickersin, NBCC co-founder, dies at 74
  • CMS rule cuts overall oncology payments by estimated 2%
    Final rule slashes 340B, moves toward site-neutrality
  • In the 90s, Barry Kramer persuaded NCI to get out of the business of screening guidelines
    At the time, USPSTF was better equipped to do the job. Is it still?

ABOUT
ABOUT
About The Cancer Letter
Accessibility Statement
Our Contributors
Editorial policies
Store
SUBSCRIPTIONS
SUBSCRIPTIONS
Our readers
Pricing
News alerts
About IP login
Job board
CONTACT
CONTACT
Contact us
Submission guidelines
Advertise
Careers
SEE ALSO
Cancer History Project
The Cancer Letter
Copyright © 2026 The Cancer Letter Inc. All rights reserved.
Privacy Policy
Terms & Conditions
FOLLOW US
Instagram
Twitter
LinkedIn
Facebook
Vimeo
Scroll to top
Request Cancellation

Subscription Change

This change will be effective immediately and your card will be charged a prorated amount based on your existing subscription level.

OK Cancel

Renew today!

Your subscription has lapsed. Subscribe today to access this content.
SUBSCRIBE NOW

Subscriber content

Log in or subscribe to access The Cancer Letter.
LOGINSUBSCRIBE NOW
SEARCH DATE
SEARCH TEXT
      Cancel
      OK
      Cancel
      OK
      Delete Account
      Are you sure you want to delete your account? This will erase all of your account data from the site. To delete your account enter your password below
      No

      Never miss an issue!

      Get alerts for our award-winning coverage in your inbox.

      Login

       
      Forgot Password?

      Site license subscribers:
      Log in with your IP | Register a sponsored account